RecruitingCIN 2/3HPV InfectionPre-Cancerous Dysplasia
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Eligible age
25–100 yrs
Accepts
Women
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Sponsor: Frantz Viral Therapeutics, LLC
You may qualify if…
- ✓ Adult females age ≥ 25 years
- ✓ Capable of informed consent
- ✓ Any HPV genotype detectable by DNA test/HPV genotyping
- ✓ Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3)
- ✓ Women of childbearing potential agree to use birth control through week17 of the study.
- ✓ Weight ≥ 50kg
You may not qualify if…
- ✕ Pregnant and nursing women
- ✕ Active autoimmune disease
- ✕ Taking immunosuppressive medication
- ✕ HIV seropositivity
- ✕ Immunocompromised subjects
- ✕ Evidence of concurrent cervical adenocarcinoma in situ
- ✕ Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects
Where it's recruiting
Source: ClinicalTrials.gov · NCT04098744 · last updated 2025-10-02